Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Relevance of Recurrent Sites of Gastric Cancer Treated With Curative Resection: A Single Center Retrospective Study

  • Received : 2024.04.01
  • Accepted : 2024.05.13
  • Published : 2024.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Gastric cancer treated with curative resection exhibits several recurrence patterns. The peritoneum is the most common site of recurrence. Some reports have indicated different prognostic influences according to the recurrence sites in other cancers, such as esophageal and colorectal cancers. This study investigated whether the recurrence sites influenced the prognosis of patients with recurrent gastric cancer. Materials and Methods: The data of 115 patients who experienced tumor recurrence after curative gastrectomy were retrospectively reviewed. The sites of recurrence were divided into 4 groups: lymph node (LN), peritoneum, other single organs, and multiple lesions. Clinicopathological features were compared between the sites of recurrence. Prognosis after resection and recurrence were also compared. Results: The peritoneum was the primary site of recurrence in 38 patients (33%). The tumor differentiation and pathological stages were significantly different. Survival after surgery did not show a statistically significant difference (hazard ratio [HR] of LN: 1, peritoneum: 1.083, other single organs: 1.025, and multiple lesions: 1.058; P=1.00). Survival after recurrence was significantly different (HR of LN, 1; peritoneum, 2.164; other single organs, 1.092; multiple lesions, 1.554; P=0.01), and patients with peritoneal and multiple lesion recurrences had worse prognosis. Furthermore, peritoneal recurrence seemed to occur later than that at other sites; the median times to recurrence in LN, peritoneal, other single-organ, and multiple lesions were 265, 722, 372, and 325 days, respectively. Conclusions: The sites of gastric cancer recurrence may have different prognostic effects. Peritoneal recurrence may be less sensitive to chemotherapy and occur during the late phase of recurrence.

Keywords

Acknowledgement

We would like to thank Editage (www.editage.com) for the English language editing.

References

  1. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet 2020;396:635-648.  https://doi.org/10.1016/S0140-6736(20)31288-5
  2. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221. https://doi.org/10.1016/S1470-2045(08)70035-4
  3. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-1069. https://doi.org/10.1016/S1470-2045(09)70259-1
  4. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6
  5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  6. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:234-247. https://doi.org/10.1016/S1470-2045(21)00692-6
  7. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:2419-2430. https://doi.org/10.1056/NEJMoa2004413
  8. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol 2012;19:1568-1574. https://doi.org/10.1245/s10434-011-2158-5
  9. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2018;21:144-154.  https://doi.org/10.1007/s10120-017-0716-7
  10. Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, et al. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg 2017;41:2337-2344. https://doi.org/10.1007/s00268-017-4024-5
  11. Ohkura Y, Shindoh J, Ueno M, Iizuka T, Udagawa H. Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection. Ann Surg Oncol 2020;27:651-659. https://doi.org/10.1245/s10434-019-08175-0
  12. Ivey GD, Johnston FM, Azad NS, Christenson ES, Lafaro KJ, Shubert CR. Current surgical management strategies for colorectal cancer liver metastases. Cancers (Basel) 2022;14:1063.
  13. Kudou K, Saeki H, Nakashima Y, Kimura Y, Oki E, Mori M, et al. Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study. Esophagus 2022;19:57-68. https://doi.org/10.1007/s10388-021-00878-2
  14. Tsai PC, Chien HC, Hsu PK, Hung JJ, Huang CS, Hsu WH, et al. Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy. BMC Cancer 2022;22:637.
  15. Tan HL, Chia CS, Tan GH, Choo SP, Tai DW, Chua CW, et al. Metastatic gastric cancer: does the site of metastasis make a difference? Asia Pac J Clin Oncol 2019;15:10-17. https://doi.org/10.1111/ajco.13025
  16. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21. https://doi.org/10.1007/s10120-020-01042-y
  17. Sohda M, Yoshida T, Nakazawa N, Ubukata Y, Kuriyama K, Hara K, et al. Comparative study on recurrence pattern and treatment method after radical esophagectomy for esophageal cancer. J Med Invest 2021;68:129-135. https://doi.org/10.2152/jmi.68.129
  18. Davini F, Ricciardi S, Zirafa CC, Romano G, Ali G, Fontanini G, et al. Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. Int J Colorectal Dis 2020;35:9-18. https://doi.org/10.1007/s00384-019-03386-z
  19. Guraya SY. Pattern, stage, and time of recurrent colorectal cancer after curative surgery. Clin Colorectal Cancer 2019;18:e223-e228. https://doi.org/10.1016/j.clcc.2019.01.003
  20. Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer 2017;20:111-121. https://doi.org/10.1007/s10120-016-0662-9
  21. Park JS, Choe EA, Park S, Nam CM, Hyung WJ, Noh SH, et al. Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Med 2021;10:3249-3260. https://doi.org/10.1002/cam4.3899
  22. Jiang Y, Zhang Z, Yuan Q, Wang W, Wang H, Li T, et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. Lancet Digit Health 2022;4:e340-e350. https://doi.org/10.1016/S2589-7500(22)00040-1
  23. Aurello P, Petrucciani N, Giulitti D, Campanella L, D'Angelo F, Ramacciato G. Pulmonary metastases from gastric cancer: Is there any indication for lung metastasectomy? A systematic review. Med Oncol 2016;33:9.
  24. Iijima Y, Akiyama H, Atari M, Fukuhara M, Nakajima Y, Kinosita H, et al. Pulmonary resection for metastatic gastric cancer. Ann Thorac Cardiovasc Surg 2016;22:230-236. https://doi.org/10.5761/atcs.oa.16-00049
  25. Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer 2018;21:338-344. https://doi.org/10.1007/s10120-017-0730-9